Search results for " hepatitis"

showing 10 items of 546 documents

Viral Hepatitis — An Update

1983

In 1973, Feinstone and co-workers [52] were the first to report the visualization of virus-like particles by immune electron microscopy in acute phase stool specimens of human volunteers who developed hepatitis following inoculation with MS-1 strain of hepatitis A virus [18]. Soon thereafter morphologically identical particles were recovered from the stool of individuals acquiring hepatitis during natural outbreaks of the disease [39, 64].

HepatitisImmune systembusiness.industryImmune serum globulinDane ParticlemedicineOutbreakHbsag carriermedicine.diseaseViral hepatitisbusinessVirologyHepatitis a virus
researchProduct

Anti-neutrophil cytoplasmic antibodies in a rat model of trinitrobenzenesulphonic acid-induced liver injury

1999

Background In sera from patients with autoimmune liver diseases, e.g. primary sclerosing cholangitis (PSC) and autoimmune hepatitis, anti-neutrophil cytoplasmic antibodies (ANCAs) can be found. Until now, no animal model of ANCA induction in liver disease has been described. In this study, we describe a novel rat model of acute liver injury and subsequent ANCA production. Materials and methods The hapten reagent 2,4,6-trinitrobenzenesulphonic acid (TNBS) was injected into the portal vein of female Lewis rats. Two experimental groups were studied: group A (TNBS/ethanol) received different TNBS concentrations; control animals of group B (ethanol) were injected with 10% (v/v) ethanol/0.9% (w/v…

HepatitisLiver injuryPathologymedicine.medical_specialtyNecrosisbusiness.industryClinical BiochemistryAutoantibodyGeneral MedicineAutoimmune hepatitismedicine.diseasedigestive systemBiochemistryPrimary sclerosing cholangitisLiver diseaseImmunologyMedicinemedicine.symptombusinessAnti-neutrophil cytoplasmic antibodyEuropean Journal of Clinical Investigation
researchProduct

Differential diagnosis of human hepatitis

2008

There is a variety of differential diagnoses of acute and chronic human hepatitis regularly seen in clinical praxis. Risk factor assessment for specific entities provides important information and should guide individual diagnostic procedures. Liver screening tests often remain the first indicator for hepatic pathologies and should include quantification of liver enzymes, liver function parameters and cholestatic parameters. Nevertheless, virus serology should always be done during further laboratory evaluation. To estimate the parenchymal liver damage and to exclude biliary obstruction or hepatic lesions an abdominal ultrasound scan is essential. A liver biopsy may complete the diagnostic …

HepatitisPathologymedicine.medical_specialtymedicine.diagnostic_testbusiness.industryAlcoholic hepatitismedicine.diseaseGastroenterologyLiver biopsyInternal medicineBiopsymedicineLiver functionDifferential diagnosisbusinessLiver function testsViral hepatitis
researchProduct

Hepatitis Due to Non-A-E Viruses

2011

HepatitisTorque teno virusViral culturebusiness.industryYellow feverCongenital cytomegalovirus infectionmedicine.disease_causemedicine.diseaseEpstein–Barr virusVirologyHerpes simplex virusmedicinebusinessAcute hepatitis
researchProduct

Autoimmune Hepatitis and Hepatitis C Virus Infection

1998

Hepatitisbiologybusiness.industryHepacivirusHepatitis C virusHepatitis C antibodyAutoantibodyHepatitis CAutoimmune hepatitisHepatitis antibodymedicine.diseasebiology.organism_classificationmedicine.disease_causeVirologymedicinebusiness
researchProduct

AB0438 Safety of tnf blockers in case of non-alcoholic fatty liver disease and cirrhosisa systematic review

2018

Background The management of inflammatory rheumatisms and psoriasis has largely evolved over the last 15 years with the emergence of biotherapies whose main adverse effect is the increased infection risk. The prevalence of metabolic syndrome is increasing and has been estimated at 30% in patients with rheumatoid arthritis with an excess of 45% compared to healthy subjects. One of the major complications of the metabolic syndrome is the Non Alcoholic Fatty Liver Disease (NAFLD), which prevalence is 25% in the global population, and 30% in a cohort of patients with rheumatoid arthritis. The main complication of NAFLD is the development of cirrhosis, known to increase infectious risk. Surprisi…

Hepatitismedicine.medical_specialtyCirrhosisbusiness.industryAutoimmune hepatitisHepatitis Bmedicine.diseaseGastroenterologyInfliximabEtanerceptInternal medicinemedicineAdalimumabLiver functionbusinessmedicine.drugRheumatoid arthritis – biological DMARDs
researchProduct

Dental considerations in patients with liver disease

2011

Introduction: Liver diseases are very common, and the main underlying causes are viral infections, alcohol abuse and lipid and carbohydrate metabolic disorders. The liver has a broad range of functions in maintaining homeostasis and health, and moreover metabolizes many drug substances. Objective: An update is provided on the oral manifestations seen in patients with viral hepatitis, alcoholic and non-alcoholic liver disease, cirrhosis and hepatocellular carcinoma, and on the dental management of such patients. Material and methods: A Medline-PubMed search was conducted of the literature over the last 15 years using the keywords: “hepatitis”, “alcoholic hepatitis”, “fatty liver”, “cirrhosis…

Hepatitismedicine.medical_specialtyCirrhosisbusiness.industryFatty liverAlcoholic hepatitisOdontologíaJaundice:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseGastroenterologyCiencias de la saludLiver diseasestomatognathic diseasesHepatocellular carcinomaInternal medicineUNESCO::CIENCIAS MÉDICASmedicinemedicine.symptombusinessViral hepatitisGeneral Dentistry
researchProduct

Autoimmune Lebererkrankungen: Diagnostik und Therapie

2004

Autoimmune Hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and overlap syndromes of these three disease entities are regarded as autoimmune liver diseases. These conditions are important differential diagnoses of elevated liver function tests as about 10 % of liver transplantations in Europe and North America are for these indications. The diagnosis is often difficult but can be facilitated by sequential measurement of relevant autoantibodies, exclusion of other liver disease, ultrasound, ERCP and liver histology. In AIH immunosuppressive therapy has been shown to prevent or stop the development of cirrhosis and improve the prognosis of the patients de…

Hepatitismedicine.medical_specialtyCirrhosismedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentGastroenterologyAutoimmune hepatitisLiver transplantationmedicine.diseaseGastroenterologydigestive system diseasesPrimary sclerosing cholangitisLiver diseasePrimary biliary cirrhosisInternal medicineImmunologyMedicinebusinessLiver function testsZeitschrift für Gastroenterologie
researchProduct

Heterozygosity for the hemochromatosis gene in liver diseases - prevalence and effects on liver histology

2000

:Background/Aims: The effect of heterozygosity for the C282Y mutation in the HFE hemochromatosis gene on iron accumulation and disease progression in liver disease patients is unclear. Methods: We investigated the prevalence of this mutation in 531 patients and 205 healthy controls. In addition, we assessed the influence of the mutation on liver histology in 34 C282Y heterozygous and 124 age-, sex- and disease-matched controls without the mutation using the modified HAI and Chevallier score. Results: The highest prevalence of the C282Y mutation was observed in patients with autoimmune hepatitis (17.2%, p<0.01) compared to 6.4% in healthy controls. Heterozygotes with hepatitis C and B virus …

Hepatitismedicine.medical_specialtyHepatologybusiness.industryAutoimmune hepatitisHepatitis CHepatitis BCompound heterozygositymedicine.diseaseGastroenterologyLiver diseasePrimary biliary cirrhosisInternal medicineImmunologymedicinebusinessHemochromatosisLiver
researchProduct

PEG IFN alfa-2a vs. alfa-2b: And the winner is …?

2009

Abstract Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. N Engl J Med 2009 Aug 6;361(6):580–93. Background Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately compared. Methods At 118 sites, patients who had HCV genotype 1 infection and who had not …

Hepatitismedicine.medical_specialtyHepatologybusiness.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseGastroenterologyChronic hepatitis HCV Head-to-head studies Pegylated interferons Ribavirindigestive system diseasesConfidence intervalSurgeryRegimenchemistry.chemical_compoundPharmacotherapystomatognathic systemchemistryTolerabilityInternal medicineMedicinebusinessAdverse effectJournal of Hepatology
researchProduct